U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations

Qing Nian1, Yihui Li2, Jingwei Li1

  • 1Department of Transfusion, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China.

Oncology Reports
|November 17, 2023
PubMed

Insights

U2 small nuclear RNA auxiliary factor 1 (U2AF1) is crucial for RNA splicing and frequently mutated in cancers. Targeting U2AF1 presents a promising therapeutic strategy for malignant diseases.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • U2 small nuclear RNA auxiliary factor 1 (U2AF1) is a key splicing factor regulating gene expression.
  • U2AF1 mutations are prevalent in hematologic malignancies and solid tumors, including lung, pancreatic, and ovarian cancers.

Approach:

  • This review summarizes pathogenic mechanisms of U2AF1 in various cancers.
  • It discusses the therapeutic potential of targeting U2AF1 and related agents.
  • The feasibility of natural product-based therapies against U2AF1 is explored.

Key Points:

  • U2AF1's role in RNA splicing and its association with diverse malignancies.
  • The significance of U2AF1 mutations in disease pathogenesis.
  • Potential therapeutic strategies targeting U2AF1.

Conclusions:

  • Targeting U2AF1 offers a viable therapeutic avenue for cancer treatment.
  • Natural products may provide novel agents for U2AF1-directed therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K